Mandate

Vinge advised Dagon in relation to expansion of its property portfolio in Gothenburg

November 02, 2010

Dagon has acquired the industrial property designated as Sävenäs 170:13 in Gothenburg from L-Å Eveberg Fastighetsutveckling AB. The property is situated adjacent to Dagon’s property designated as Sävenäs 170:14 on von Utfallsgatan in Gothenburg. The purchase price was based on a total underlying property value of SEK 16. 9 million. Completion was scheduled to occur on 1 November 2010. The acquisition was effected through a share transfer of the real estate holding company.

Dagon also acquired two properties designated as Tuve 86:2 and Tynnered 1: 15 in Gothenburg. The properties are currently fully let and annual rental income amounts to approximately SEK 6.4 million. The purchase price was based on a total underlying property value of SEK 72.5 million. Completion was scheduled to occur on 1 November 2010.

Dagon AB (publ) is a property development company with an estate portfolio with a market value of approximately SEK 5 billion. The portfolio primarily consists of commercial properties and some project development properties in southern and central Sweden. Dagon AB is listed on NASDAQ OMX Stockholm.

Vinge’s team consisted of Olof Jisland and Ulf Käll.

Related

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024